Athenex (NASDAQ:ATNX – Get Rating) and ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.
Earnings and Valuation
This table compares Athenex and ImmunoPrecise Antibodies' gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Athenex||$120.18 million||1.11||-$199.77 million||($1.72)||-0.64|
|ImmunoPrecise Antibodies||$15.32 million||6.89||-$13.32 million||($0.68)||-6.25|
ImmunoPrecise Antibodies has lower revenue, but higher earnings than Athenex. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Athenex, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
This table compares Athenex and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
40.9% of Athenex shares are held by institutional investors. Comparatively, 6.6% of ImmunoPrecise Antibodies shares are held by institutional investors. 12.0% of Athenex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Athenex and ImmunoPrecise Antibodies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Athenex presently has a consensus price target of $4.00, suggesting a potential upside of 263.64%. ImmunoPrecise Antibodies has a consensus price target of $12.00, suggesting a potential upside of 182.35%. Given Athenex's higher probable upside, research analysts plainly believe Athenex is more favorable than ImmunoPrecise Antibodies.
ImmunoPrecise Antibodies beats Athenex on 7 of the 13 factors compared between the two stocks.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Athenex，Inc.是一家生物制药公司，从事癌症治疗药物的发现、开发和商业化。它通过三个部分运作：肿瘤学创新平台、全球供应链平台和商业平台。该公司的Orascovery候选产品包括口服紫杉醇和Enequidar，这是一种口服剂型，正处于转移性乳腺癌的第三阶段试验，以及针对皮肤血管肉瘤、进展期胃癌和进展期实体恶性肿瘤的各种临床研究。它还提供由替巴尼布林软膏组成的Src Kinase候选产品，用于治疗光化性角化病、皮肤癌和牛皮癣。此外，该公司正在开发KUR-501，这是一种用于治疗复发难治性(R/R)高风险神经母细胞瘤的儿童的自体产品，处于I期临床试验；KUR-502，这是一种同种异体产品，处于治疗成人R/R CD19阳性恶性肿瘤的第一阶段临床试验，包括B细胞淋巴瘤、急性淋巴细胞白血病和慢性淋巴细胞白血病；以及KUR-503，这是一种处于晚期肝细胞癌临床前开发的同种异体产品，以及TCRT-ESO-A2，一种自体T细胞受体(TCR)T细胞疗法，处于实体肿瘤的第一阶段临床试验。此外，它正在开发双重吸收增强剂，以抑制胃肠道内的P-gp转运体和细胞色素P450 3A酶；并拥有一系列TCR，可识别多种肿瘤的P53、KRAS和EGFR基因的热点突变。该公司前身为Kinex PharmPharmticals LLC，并于2015年8月更名为Athenex，Inc.Athenex，Inc.成立于2003年，总部设在纽约州布法罗。
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
免疫精抗体有限公司及其子公司在美国、加拿大、欧洲和国际上从事抗体生产和相关服务。该公司提供一系列抗体、酶、酶活性分析、关节炎动物产品、蛋白质、去亚胺蛋白、有机生长因子和杂交瘤产品用于研究目的。其服务包括定制抗原建模、设计和制造；B细胞分类、筛选和测序；定制、免疫和天然噬菌体展示生产和筛选；转基因动物和多物种抗体发现；双特异性、三特异性、VHH和VNAR(鲨鱼)抗体制造；DNA克隆、蛋白质和抗体的下游加工；无标记生物传感器和抗体工程的抗体表征；瞬时和稳定的细胞系生成；抗体优化和人性化；多重杂交瘤的生产、高通量筛选和克隆挑选；以及冷冻保存。该公司与Pierre Fabre S.A公司签订了抗体发现方面的研究合作协议，并与Elektrofi公司签订了研究合作协议，以探索高浓度新冠肺炎抗体鸡尾酒配方多表位TATX-03。免疫精抗体有限公司成立于1983年，总部设在加拿大维多利亚。
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.